Name: CB-839
Price: 255.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    CB-839(Telaglenastat) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC(glutaminase C)[1].
    CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D[1].
    In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%[1].
    
    [1]. Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901.
- Properties
  - Alternative Name
    
    2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide
    
    CAS Number
    
    1439399-58-2
    
    Molecular Formula
    
    C26H24F3N7O3S
    
    Molecular Weight
    
    571.57
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥28.6 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Momcilovic M, Bailey ST, et al. "The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma." Cancer Cell. 2018 May 14;33(5):905-921.e5. PMID:29763624

CB-839

CB-839

Background

We Also Recommend

Defactinib

Firocoxib

PEAQX